

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 211/60	A1	(11) International Publication Number: WO 96/22281 (43) International Publication Date: 25 July 1996 (25.07.96)
(21) International Application Number: PCT/GB96/00067 (22) International Filing Date: 12 January 1996 (12.01.96) (30) Priority Data: 9501071.6 18 January 1995 (18.01.95) GB (71) Applicant (for all designated States except US): CHIRO-SCIENCE LIMITED [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): DYER, Ulrich, Conrad [GB/GB]; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). LANGSTON, Marianne [GB/GB]; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). WOODS, Martin [GB/GB]; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: RACEMISATION PROCESS FOR USE IN THE MANUFACTURE OF LEVOBUPIVACAINE AND RELATED PIPERIDINECARBOXANILIDE ANAESTHETIC AGENTS		
(57) Abstract An optically-enriched piperidine-2-carboxanilide compound, in which the piperidine is optionally N-alkylated, is racemised by heating the compound in an aqueous medium, provided that the medium includes an organic cosolvent if the compound is N-alkylated. This process is particularly valuable, in conjunction with a resolution process, for the manufacture of levobupivacaine.		

FOR THE PURPOSES OF INFORMATION ONLY.

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

RACEMISATION PROCESS FOR USE IN THE MANUFACTURE OF
LEVOBUPIVACAINE AND RELATED PIPERIDINECARBOXANILIDE
ANAESTHETIC AGENTS


Field of the Invention

5 This invention relates to the racemisation of optically-enriched piperidine-2-carboxanilides. In particular, the process is suitable for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents.

10 Background to the Invention

Compounds of formula 1

15



wherein R² is 2,6-dimethylphenyl and R¹ is methyl
20 (mepivacaine), *n*-propyl (ropivacaine as *S*-enantiomer) or *n*-butyl (bupivacaine) are widely used as local anaesthetics. The corresponding compound when R¹ is H is a useful intermediate.

Biological studies have shown that the (*S*)-enantiomers
25 of such N-alkyl-piperidine-2-carboxanilides display lower cardiotoxicity than the corresponding racemates, whilst maintaining the same anaesthetic potency, and are therefore more beneficial for clinical uses. Thus there is a requirement for efficient processes to manufacture
30 compounds of formula 1 in the form of single enantiomers. For this purpose, conventional resolution approaches invariably afford up to 50% of the unwanted enantiomer. To improve atom utilisation in such processes, it is desirable to recycle the unwanted enantiomer by effecting its
35 racemisation in order to provide material suitable for subsequent resolution.

Friberger et al, Acta. Pharm. Suec. (1971) 8:361-364, report a study of the solubility and partition coefficients of the racemates and enantiomers of mepivacaine and bupivacaine. It is reported that racemic bupivacaine is more soluble than the isomers at a pH above 6. All of the compounds tested have solubilities decreasing to low levels, especially for bupivacaine, at pH values approaching neutrality.

Fyhr et al, Acta. Pharm. Suec. (1988) 25:121-132, report the racemisation of optically-enriched ropivacaine hydrochloride in dilute aqueous solution at pH 1-6 and 80-130°C. HCl or citric acid was present, in order to establish the pH. The conclusions of this pre-formulation stability study were that the racemisation involves hydroxyl ion-catalysed racemisation of the N-protonated species. This study provides no useful indication as to how to conduct racemisation as such, and does not suggest any volume-efficient commercial process.

Summary of the Invention

The present invention is based on the surprising discovery that piperidine-2-carboxanilides, including compounds of formula 1 wherein R¹ is H, methyl, n-propyl or n-butyl and R² is 2,6-dimethylphenyl, undergo rapid racemisation when heated in aqueous solution, provided that an organic cosolvent is present when R¹ is not H. The practical nature of this discovery is evident in that much more concentrated systems can be used than in the prior art.

Whereas, at concentrations of 30 mg/ml, at a pH above 5, the use of conditions otherwise specified by Fyhr et al lead to complete inhibition of racemisation of ropivacaine and bupivacaine, the rate of racemisation can be increased, under the conditions used in this invention, with increasing pH of the solution. Racemisation occurs most efficiently at a pH greater than 6, without loss of solubility, which means that no acid need be added.

Description of the Invention

The reaction can be carried out in water alone, when R^1 is H. In this case, a preferred embodiment of the invention is the racemisation of optically-enriched 2',6'-
5 dimethylpiperidine-2-carboxanilide (1: $R^1 = H$, $R^2 = 2,6$ -dimethylphenyl).

Alternatively, for N-alkylpiperidine compounds of formula 1, the reaction is carried out in the presence of an organic cosolvent such as an alcohol or polyol, e.g.
10 ethylene glycol thus allowing solutions of higher concentration to be used, than in the prior art. A preferred embodiment of this aspect of the invention is the racemisation of optically-enriched bupivacaine in ethylene glycol containing 10% v/v water. The presence of salt
15 forms of compounds of formula 1 does not impede the efficiency of the racemisation process.

The reaction conditions may comprise heating, as desired. Suitable conditions will depend on the nature of the reactants, but can be readily chosen by those skilled
20 in the art.

In summary, the present invention establishes simple and economical processes for the racemisation of piperidine-2-carboxanilides, in either neat aqueous media or aqueous media combined with inert organic cosolvents.
25 The invention is particularly suited to the optimum utilisation of unwanted enantiomer in the preparation of enantiopure therapeutic agents, and therefore in practice the starting material will usually be richer in the (*R*)-enantiomer. When R^1 is H, a compound of formula 1 is an
30 intermediate en route to anaesthetic agents. When R^1 is *n*-butyl, the present invention is of particular utility for preparing (*S*)-bupivacaine, in conjunction with a resolution process, e.g. that described in PCT/GB95/02513 and South African Application No. 95/8993.

35 The following Examples illustrate the invention.

Example 1

(*S*)-2',6'-Dimethylpiperidine-2-carboxanilide (>99% ee, 155 mg, 0.67 mmol) was dissolved in water (14.5 ml). The pH was measured to be 9.97. The solution was heated under reflux for 19 hours. Aqueous ammonia (28% w/v; 1 ml) was added to the cooled solution and the mixture extracted with ethyl acetate (2 x 20 ml). The combined organic layers were dried with magnesium sulphate and the solvent removed under reduced pressure to give a white crystalline solid (128 mg). Analysis by chiral HPLC showed this to be racemic 2',6'-dimethylpiperidine-2-carboxanilide.

Example 2

A mixture of (*S*)-bupivacaine (>99% ee, 1.5 g mmol), ethylene glycol (13.5 ml) and water (1.5 ml) was heated at 138°C for 9 hours. On cooling to ambient temperature crystallisation of a solid occurred. The solid was filtered to give a quantitative yield of bupivacaine which was shown by chiral HPLC analysis to be a 52:48 mixture of (*S*)-bupivacaine and (*R*)-bupivacaine.


Example 3

(*S*)-Bupivacaine (>99% ee, 0.27 g, 0.94 mmol) and (*S*)-bupivacaine (-)-tartrate (2:1 salt, 0.23 g, 0.32 mmol) were heated at 150 °C in propan-2-ol (2.5 ml) and water (2.5 ml) in a sealed vessel for 22 hours. A portion of solution was removed, basified with 28% aqueous ammonia and extracted into heptane. The organic solution was dried with magnesium sulphate and the solvent removed under reduced pressure. The residue was shown by chiral HPLC to be a 63:37 mixture of (*S*)-bupivacaine and (*R*)-bupivacaine.

CLAIMS

1. A process for the racemisation of an optically-enriched piperidine-2-carboxanilide compound, in which the piperidine is optionally N-alkylated, which comprises
5 heating the compound in an aqueous medium, provided that the medium includes an organic cosolvent if the compound is N-alkylated.
2. A process according to claim 1, wherein a salt form of the compound is also present.
- 10 3. A process according to either preceding claim, which is conducted at a pH above 6.
4. A process according to any preceding claim, which is conducted in the absence of added acid.
5. A process according to any preceding claim, where said
15 compound is enriched in the (R)-enantiomer.
6. A process according to any preceding claim, wherein the compound is of the formula

20



25

- wherein R¹ is H or a substituent of up to 20 C atoms and R² is C₆₋₂₀ aryl.
7. A process according to claim 6, wherein R¹ is H or C₁₋₆ alkyl and R² is phenyl optionally substituted with one or more C₁₋₄ alkyl groups.
8. A process according to claim 7, wherein R² is 2,6-
30 dimethylphenyl.
9. A process according to any preceding claim, wherein the medium comprises water and an organic cosolvent.
10. A process according to claim 9, wherein the cosolvent is an alcohol or polyol.
- 35 11. A process according to claim 9, wherein the cosolvent is an ethylene glycol.

12. A process according to claim 8, or to any of claims 9 to 11 when appendant to claim 8, wherein R¹ is n-butyl, for preparing bupivacaine of diminished optical purity.
13. A process according to claim 8, or to any of claims 9 to 11 when appendant to claim 8, wherein R¹ is n-propyl.
14. A process according to claim 8, wherein R¹ is H, for the racemisation of 2',6'-dimethylpiperidine-2-carboxanilide.
15. A process according to any of claims 6, 7, 8 and 14, wherein R¹ is H and the medium consists essentially only of water.
16. A process for preparing (S)-bupivacaine, which comprises resolving a mixture of enantiomers of bupivacaine, separating (S)-bupivacaine, and racemising residual (R)-bupivacaine by a process according to claim 12, prior to further resolution.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/GB 96/00067

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D211/60

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ACTA PHARMACEUTICA SUECICA, vol. 25, no. 3, 1988 pages 121-132, P. FYHR, C. HOGSTROEM 'A Preformulation Study on the Kinetics of the Racemisation of Ropivacaine Hydrochloride' cited in the application see top paragraph on page 131 ---	1-16
A	J. ORG. CHEM., vol. 48, 1983 pages 843-846, S. YAMADA ET. AL. 'Method for the Racemisation of Optically Active Amino Acids' see the whole document --- -/--	1-16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

29 March 1996

Date of mailing of the international search report

03.04.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Kissler, B

INTERNATIONAL SEARCH REPORT

Int onal Application No
PCT/GB 96/00067

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. ORG. CHEM., vol. 43, no. 1, 6 January 1978 pages 1-5, G.G. SMITH ET. AL. 'Factors Affecting the Rate of Racemisation of Amino Acids and Their Significance to Geochronology' page 2, right column, top paragraph: "Buffer and pH" ---	1-16
X	FR,A,2 301 498 (MAGGIONI & C.) 17 September 1976 see the whole document ---	1-16
A	BULL. CHEM. SOC. JPN., vol. 64, 1991 pages 3251-3255, T. SHIRAIWA ET. AL. 'Asymmetric Transformation of Proline and 2-Piperidinecarboxylic Acid via Formation of Salts with Optically Active Tartaric Acid' see the whole document ---	1-16
A	CHEM. PHARM. BULL., vol. 18, no. 9, September 1970 pages 1794-1798, M. SATO ET. AL. 'Studies on the Racemisation of Amino Acids and Their Derivatives' see the whole document -----	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int onal Application No

PCT/GB 96/00067

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2301498	17-09-76	NONE	